Joint Core Facilities & Medical and Clinical Research
Over the past decade, Kyoto University has also increasingly invested in various new programs, facilities, and financing schemes to support start-up companies founded by scientists affiliated with the university.
Working with Industry
Estimated at 10s of billion of US$ today, the market for cancer immunotherapy drugs today is likely to grow over the next decades as enhance treatment are becoming available to an increasing number of patients in developed and increasingly also in developing countries.
CCII’s New Research Building
CCII’s new home, the Bristol Myers Squibb Building at the Center for Cancer Immunotherapy and Immunobiology at the Kyoto University campus, has been made possible by funding from the Japanese government and a generous donation from pharmaceutical giant Bristol Myers Squibb.
Advancing Cancer Immunotherapy in Japan
Funding for CCII is provided for the most part through public grants. In addition, CCII’s activities are also supported by donations from corporations and individuals, as well as through joint research with industry…